Download presentation
Presentation is loading. Please wait.
Published byAirton Viveiros Gonçalves Modified over 6 years ago
1
Safety of etanercept in patients with psoriasis and hepatitis C virus assessed by liver histopathology: Preliminary data Andrea Paradisi, MD, Giacomo Caldarola, MD, Rodolfo Capizzi, MD, Massimo Siciliano, MD, Eleonora Annichiarico, MD, Fabio Maria Vecchio, MD, Pier Luigi Amerio, MD, Clara De Simone, MD Journal of the American Academy of Dermatology Volume 62, Issue 6, Pages e2 (June 2010) DOI: /j.jaad Copyright © 2009 American Academy of Dermatology, Inc. Terms and Conditions
2
Fig 1 Serum transaminase and viral load during etanercept treatment in patients 1 (A) and 2 (B). Journal of the American Academy of Dermatology , e2DOI: ( /j.jaad ) Copyright © 2009 American Academy of Dermatology, Inc. Terms and Conditions
3
Fig 2 Liver biopsy specimens obtained before etanercept therapy (A and C) and 12 months into treatment (B and D) in patients 1 and 2, respectively. To see the images in greater detail, please visit where you can enlarge them using your Internet browser. (Hematoxylin–eosin stain.) Journal of the American Academy of Dermatology , e2DOI: ( /j.jaad ) Copyright © 2009 American Academy of Dermatology, Inc. Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.